Related Experiment Video
Updated: May 12, 2026

Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
Effectiveness of Continuous Glucose Monitoring on Glycemic and Metabolic Outcomes in Type 2 Diabetes: A Two-Year
Ayman Al Hayek1,2,3, Wael M Al Zahrani1, Haifa F Alotaibi2
1Department of Endocrinology and Diabetes, Diabetes Treatment Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Background:
To evaluate whether sustained use of continuous glucose monitoring (CGM) is associated with long-term patterns in glycemic control, safety indicators, and health care utilization among adults with type 2 diabetes (T2D) in routine clinical care.
Method:
A two-year retrospective chart review was conducted at a tertiary care center in Saudi Arabia. Adults with T2D who initiated second-generation CGM (FreeStyle Libre 2) and maintained use for 24 months were included. Glycemic, metabolic, and clinical outcomes were assessed at baseline, 12 months (T12), and 24 months (T24).
Results:
Among 222 adults (mean age 48.7 years; 48.2% female), sustained CGM use was associated with improvements across multiple glycemic parameters. Glycated hemoglobin (HbA1c) declined from 8.2% at baseline to 7.8% at T24, accompanied by reductions in mean glucose, self-monitoring of blood glucose frequency, glycemia risk indices, and glucose variability. %TIR70-180 increased, time spent in hyperglycemia decreased, and time below range remained low throughout follow-up. Directionally similar glycemic improvements were observed across subgroups, including individuals with obesity, those treated with oral agents only, and those receiving insulin-based regimens. Beyond glycemic outcomes, body weight decreased by approximately 2 kg over 24 months. Diabetes-related emergency department visits declined from five participants (2.3%) at T0 to two (0.9%) at T12 and one (0.5%) at T24.
Conclusions:
Two-year use of CGM in routine care was associated with favorable trends in glycemic control, glycemic stability, self-monitoring behavior, and health care utilization. Long-term CGM integration may be feasible and potentially beneficial across diverse T2D populations, although prospective studies are needed to clarify the causal effects.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type II Diabetes II: Pathophysiology
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...